

	Type	L #	Hits	Search Text	DBs	Time Stamp	Comments	Error Definition	Errors
5	BRS	L7	0	6 same 2	USPAT; US-PGP UB; EPO; JPO; DERWEN T	2001/06/04 17:58			0
6	BRS	L8	32	4 near (human or murine or rabbit or rat)	USPAT; US-PGP UB; EPO; JPO; DERWEN T	2001/06/04 17:58			0
7	BRS	L9	0	8 same 2	USPAT; US-PGP UB; EPO; JPO; DERWEN T	2001/06/04 17:58			0
8	BRS	L11	36	(limulus adj anti-LPS adj factor) or LALF	USPAT; US-PGP UB; EPO; JPO; DERWEN T	2001/06/04 18:00			0
9	BRS	L14	0	12 same 2	USPAT	2001/06/04 18:02			0

	Type	L #	Hits	Search Text	DBs	Time Stamp	Comments	Error Definition	Error Definitors
10	BRS	L15	78	4 same (treating or treatment)	USPAT; US-PPG UB; EPO; JPO; DERWEN T	2001/06/04 18:04		0	
11	BRS	L16	1069	(bactericidal adj permeability adj increasing adj protein) or BPI	USPAT; US-PPG UB; EPO; JPO; DERWEN T	2001/06/04 18:06		0	
12	BRS	L17	99	(16 or 11) same 4	USPAT; US-PPG UB; EPO; JPO; DERWEN T	2001/06/04 18:38		0	
13	BRS	L18	11	17 same (hybrid adj protein)	USPAT; US-PPG UB; EPO; JPO; DERWEN T	2001/06/04 18:40		0	

	Type	L #	Hits	Search Text	DBs	Time Stamp	Comments	Error Definition	Error Counters
14	BRS	L19	26	17 same (fusion adj protein)	USPAT; US-PPG UB; EPO; JPO; DERWEN T	2001/06/04 18:45		0	

	Type	L #	Hits	Search Text	DBs	Time Stamp	Comments	Error Definition	Error Definitors
1	BRS	L2	1492	septicemia	USPAT; US-PGP UB; EPO; JPO; DERWEN T	2001/06/04 17:54		0	
2	BRS	L4	1957	lbp or (liposaccharide adj binding adj protein)	USPAT; US-PGP UB; EPO; JPO; DERWEN T	2001/06/04 18:03		0	
3	BRS	L5	0	2 same 4	USPAT; US-PGP UB; EPO; JPO; DERWEN T	2001/06/04 17:55		0	
4	BRS	L6	71	4 same (variant or mutant or hybrid)	USPAT; US-PGP UB; EPO; JPO; DERWEN T	2001/06/04 17:57		0	

STN INTERNATIONAL LOGOFF AT 07:33:36 ON 05 JUN 2001

```

=> Log Y
COST IN U.S. DOLLARS
SINCE FILE    TOTAL    SESSION ENTRY    FULL ESTIMATED COST
171.41        171.56    SESSION ENTRY    DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)
SINCE FILE    TOTAL    SESSION ENTRY    CA SUBSCRIBER PRICE
171.41        171.56    -24.70      -24.70

```

```

FILE 'MEDLINE', CAPLUS, BIOSIS, EMBASE', ENTERED AT 07:13:54 ON 05 JUN 2001
3340 S LBP OR (LIPOSACCHARIDE BINDING PROTEIN)
153 S L1 (P) (VARIANT OR MUTANT OR HYBRID)
46210 S SEPTICEMIA
14 S (L1 OR L2) (P) L3
6 DUPLICATE REMOVE L4 (3 DUPLICATES REMOVED)
2522 S (L1 OR L2) (A) (HUMAN OR MURINE OR RABBIT OR RAT)
17 729 S (L1 OR L2 OR L6) (P) TREAT?
402 DUPLICATE REMOVE L7 (327 DUPLICATES REMOVED)
65 S L8 AND (COMPOSITION OR AGENT)
2229 S (BACTERICIDAL PERMEABILITY INCREASING PROTEIN) OR BPI
L10 64 S (LIMULUS ANTI-LPS FACTOR) OR LALP
15 S (L1 OR L2 OR L6) (P) L11
9 DUPPLICATE REMOVE L12 (6 DUPLICATES REMOVED)
L13

```

From Escherichia coli, Klebsiella pneumoniae, Pseudomonas aeruginosa, and **Serratia marcescens**, (2) bacterial **antimicrobial activity** against these same found gram-negative bacteria in vitro. **RESULTS**. Syntetic peptides BG38 (BPI-derived), BG42 (***LALF*** -derived), and BG43 (***LBP*** -derived) but not control peptide significantly inhibited LPS-induced tumor necrosis factor-alpha secretion by macrophages and mediated the LPS of gram-negative bacteria in vitro. In addition, preincubation of LPS with peptide BG38 mediated complete protection subsequent to Lethal endotoxin challenge. **CONCLUSIONS**. These data demonstrate that small peptides derived from BPI, ***LALF***, and ***LBP***, retained significant **antimicrobial activity** and **neutralizing ability** against many different gram-negative bacteria in vitro. **Identification** of this conserved LPS-binding region within each protein may aid in the development of new immunomodulatory reagents for use as adjunctive therapy in the treatment of gram-negative bacterial infection.